Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D Outcomes in Older Adults: Full Evidence Review

Previous related pageVitamin D Outcomes in Older Adults: Study SummaryNext related pageVitamin D Outcomes in Older Adults: Study Summary
Study at a glance

What question did the studies ask?

Does vitamin D reduce fractures, falls or infections, or improve function and other outcomes in older adults? Trials included women in residential care and generally healthier people living in the community. Some other trials included middle-aged as well as older adults.

What did they find?

One residential-care trial found fewer fractures with vitamin D3 plus calcium. Vitamin D3 alone did not demonstrate fewer fractures in a large community trial. Other trials did not demonstrate benefits on their main physical-function or infection outcomes. Higher doses did not clearly prevent falls, and some analyses raised concern about serious falls.

What does this mean?

Age alone does not describe nutrition, mobility or kidney function. Benefits from combined vitamin D and calcium cannot be assigned to vitamin D alone. An uncertain possible heart benefit and combined diabetes findings do not establish benefits for all older adults.

What are the limits?

Frail people and some severely deficient groups remain less well studied. Uncertainty does not prove they would benefit. Some reports described harms; a report of more deaths available only as an abstract could not be fully assessed. Research treatments are not individual treatment instructions.

Read the full article below ↓

Older adults differ in mobility, nutrition, kidney function, residence and underlying disease. Those differences affect both vitamin D status and the relevance of supplementation trials. This review compares musculoskeletal, immune and metabolic outcomes while asking which older people were actually studied. It separates evidence from relatively healthy community volunteers from evidence in residential settings, and distinguishes ordinary physiological roles from a demonstrated benefit of additional treatment. Read the shorter account, Vitamin D Outcomes in Older Adults: Study Summary.

Chronological age does not define one study population

A person in their sixties living independently and a frail resident in their eighties may both be described as an older adult. Their baseline fracture risk, dietary calcium, outdoor exposure and capacity to complete physical tests can differ substantially. A trial’s average age therefore cannot establish its relevance to every older population.

Eligibility criteria matter as much as age. Trials may exclude severe disease, osteoporosis, substantial kidney impairment or high supplement use. Participants who volunteer and remain in follow-up can also be healthier than the population to which readers wish to apply the results.

These differences are not reasons to disregard a well-conducted trial. They define the setting in which its estimate is most informative. They also prevent an apparently simple reconciliation in which every null result is blamed on healthy participants and every positive result is assumed to apply universally. The broader ageing subject is introduced in Vitamin D and Age-Related Decline.

A combined intervention reduced fractures in residential women

Chapuy and colleagues (1992) studied 3,270 ambulant older women in nursing homes and residential accommodation. Mean age was approximately 84 years. The trial compared a combined vitamin D3 and calcium preparation with double placebo over 18 months, in a setting of relatively low calcium intake.

The intention-to-treat counts included 80 hip fractures in the active group and 110 in the placebo group. The corresponding nonvertebral fracture counts were 160 and 215. These findings provide positive evidence for the combined intervention in that population. They should not be replaced by the larger percentage reduction reported among participants who completed follow-up.

Only about half completed the full 18 months, and biochemical and bone-density measurements came from much smaller subsets. Calcium and phosphate accompanied vitamin D3, so the trial cannot isolate a vitamin D-alone effect. Its setting, cointervention and baseline risk are central to its interpretation, not incidental details. The skeletal physiology background is introduced in Vitamin D and Bone.

VITAL tested a different population and intervention

LeBoff and colleagues (2022) reported fractures in VITAL, a large trial of vitamin D3 at 2,000 IU daily. Participants were men aged at least 50 and women aged at least 55, with a mean age around 67 years. They were not recruited specifically for osteoporosis or vitamin D deficiency.

The trial did not demonstrate a reduction in total fractures, with a hazard ratio of 0.98 and a 95% confidence interval of 0.89 to 1.08. The hip-fracture estimate was also uncertain. These results directly inform additional vitamin D3 in a broadly healthier community population.

VITAL and Chapuy therefore should not be treated as identical experiments giving contradictory answers. They differ in age distribution, residence, baseline nutrition and calcium coadministration. Those differences can help frame the comparison, but they do not identify which single factor explains the difference. Neither study randomly assigned participants between the two settings.

Falls trials also depend on the comparator

STURDY, reported by Appel and colleagues (2021), enrolled 688 adults aged 70 or older with increased fall risk and relatively low vitamin D concentrations. Its adaptive design compared daily doses with an active 200 IU control. It was not a simple vitamin D-versus-no-vitamin-D experiment.

The selected higher dose did not demonstrate the intended reduction in falls. Some analyses identified more serious falls or falls requiring hospitalisation with higher-dose exposure. These signals matter because an intervention proposed to improve strength or balance must also be evaluated against the outcome of actually falling.

The adaptive dose selection and different analysis populations require care. Results from the selected-dose comparison are not interchangeable with the original whole-trial comparison. The trial does not establish that all vitamin D doses increase falls, but it strongly cautions against assuming that more vitamin D produces greater protection in older people at risk. Muscle function is a related but distinct subject, introduced in Vitamin D and Muscle Function.

DO-HEALTH examined function and infections together

Bischoff-Ferrari and colleagues (2020) enrolled 2,157 relatively healthy adults aged 70 or older in DO-HEALTH. The trial tested vitamin D3, omega-3 supplementation and a home exercise programme in a factorial design over three years. It assessed several primary outcomes, including blood pressure, physical performance, infections and nonvertebral fractures.

Vitamin D did not demonstrate benefit on the primary outcomes. Interpretation must retain the factorial analysis: interactions meant that the infection and physical-performance comparisons used the vitamin D-only and placebo-only groups rather than simply pooling all participants assigned vitamin D against all others.

The cohort was generally active and functioning well. That can reduce the opportunity to improve a physical-performance score. It does not make the null findings uninformative, and it does not prove that a frailer group would benefit. The trial also used stricter significance criteria across its multiple primary questions, which should not be replaced by selecting a nominally favourable secondary result. The distinction between a concentration and functional response is introduced in Functional Vitamin D Status. The limits of biochemical response classifications are assessed in Functional Vitamin D Status: Biological Response Beyond Circulating Levels: Full Study.

Low physical function does not guarantee responsiveness

A separate trial by Houston and colleagues (2023) specifically enrolled low-functioning older adults. Its abstract reports no demonstrated benefit of vitamin D3 on leg power, strength or physical performance. The complete principal paper was unavailable for this review, so that report is used only as qualitative, access-limited background.

Its relevance is a constraint on interpretation: it prevents portraying every negative muscle trial as involving participants with high starting function. The study’s full methods and detailed results are required before making a precise comparison of functional effects or safety.

The publication’s correction also matters when reading its abstract: 30 ng/mL corresponds to 75 nmol/L, not 50 nmol/L. Blood-unit conversion should not change the apparent population being studied. This example reinforces why an age label or a short abstract cannot replace careful attention to eligibility and measurements.

Infection outcomes do not measure immune rejuvenation

DO-HEALTH’s infection results concern recorded infection events under the tested interventions. They do not measure every aspect of immune function or demonstrate whether an older person’s immune system has become younger. A cellular mechanism, an inflammatory marker and a clinical infection are different endpoints.

The VITAL autoimmune programme supplies another immune-related outcome, but it is not equivalent to infection resistance. Extended follow-up reported by Costenbader and colleagues (2024) weakened an earlier favourable vitamin D interpretation. Late confirmation of cases also revised the estimate for the original intervention period, rather than only showing what happened after supplementation ended.

This matters in older-adult discussions because a broad claim of preserved immune competence could otherwise be constructed from several neighbouring outcomes that were never measured as one process. Evidence should remain attached to the specific disease definition and follow-up period. Uncertainty about severely deficient or frail populations remains uncertainty, not a demonstrated benefit waiting to be assumed. The wider mechanism-to-outcome comparison is examined in Vitamin D, Immune Tolerance Mechanisms and Autoimmune Outcomes: Full Evidence Review.

Cardiovascular results were suggestive but not definitive

Thompson and colleagues (2023) examined major cardiovascular events in D-Health. Australians aged 60 to 84 were assigned monthly vitamin D3 at 60,000 IU or placebo for five years. The cardiovascular analysis included more than 21,000 participants and used linked health records.

The overall cardiovascular hazard ratio was 0.91, with a 95% confidence interval of 0.81 to 1.01. The absolute difference was approximately 5.8 fewer events per 1,000 participants, with an interval extending from 12.2 fewer to 0.5 more. The estimate was compatible with a modest benefit, but did not establish it conclusively.

Cardiovascular events were a tertiary outcome among many analyses. A nominally favourable myocardial-infarction result cannot establish overall prevention by itself. Starting vitamin D status was predicted rather than measured in all participants, limiting subgroup interpretation. The findings should not be used to recommend monthly high-dose supplementation to older adults.

Metabolic evidence is not specifically geriatric evidence

D2d and DPVD examined progression to diabetes in people with prediabetes, with mean ages around 60 to 61 years. Their individual primary comparisons were uncertain, while the 2023 individual-participant meta-analysis by Pittas and colleagues found a modest pooled reduction in progression.

That positive aggregate finding should remain visible. However, these are mixed-age, selected prediabetes populations, not trials designed to establish effects in frail people in their eighties or nineties. DPVD also used an active analogue, eldecalcitol, rather than nutritional vitamin D3.

The evidence therefore supports a qualified metabolic discussion without establishing a geriatric treatment rule. Achieved blood concentrations were not separately randomised treatment targets. Neither a pooled benefit nor a favourable observational association proves that increasing a particular older person’s blood result will improve glucose regulation or general metabolic resilience.

Aggregate fracture evidence preserves both relative and absolute effects

Massé and colleagues’ 2026 systematic review found no clear pooled fracture or falls benefit from vitamin D alone. Some combined calcium and vitamin D comparisons did show statistically significant relative reductions in fractures. The authors judged their absolute size small against selected thresholds for clinical importance.

Both parts of that statement matter. A small absolute benefit is not the same as an estimate centred on no effect. Conversely, a relative reduction can correspond to a small absolute difference when baseline risk is low. Benefits in higher-risk settings should not be erased by a single pooled average.

The combined estimates were influenced by the Chapuy programme. Removing an influential study in a sensitivity analysis changes the result, but does not make the original trial disappear. The review also cannot assign a combined calcium-vitamin D effect solely to vitamin D. Its predominantly community-based evidence leaves some frail and severely deficient populations less directly represented.

Safety and uncertainty must remain part of the conclusion

STURDY’s serious-fall signals show why potential harms belong beside proposed benefits. TIPS-3 also reported higher mortality under vitamin D assignment in its abstract. Its complete principal report was unavailable here, so this remains explicitly access-limited contrary evidence, not a definitive explanation of mortality risk.

The existence of that signal prevents a blanket claim that higher-dose supplementation is harmless. Equally, it does not prove that every form, dose or clinical use of vitamin D causes harm. Regimen, population and outcome matter in safety interpretation just as they do in efficacy interpretation.

The combined evidence is most useful when these distinctions are preserved. Some older residential women benefited from a combined intervention; several large community trials did not establish vitamin D-alone benefits on their principal outcomes; some comparisons raised concern about harm. These findings do not reduce to one instruction for everyone above a particular age. They inform specified clinical questions and leave individual assessment, deficiency treatment and prescribed care to appropriate healthcare evaluation. Separate experimental and exercise-related muscle evidence is assessed in Vitamin D Receptors, Muscle Protein Synthesis and Adaptation: Evidence Review.

Sources

Related reading

Physiology

Vitamin D in Older Adults

Explore how vitamin D participates in later-life physiology, supporting regulatory balance across skeletal, immune, metabolic, neuromuscular, and neuroendocrine systems.

Read more →

Original sources

Source

Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial

Published in Bischoff-Ferrari HA et al (2020).

Publication details

Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. Bischoff-Ferrari HA et al. 2020. JAMA. Volume 324(18); pages/article 1855-1868. DOI: 10.1001/jama.2020.16909.

Read more →
Source

Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial

Published in Costenbader KH et al (2024).

Publication details

Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Costenbader KH et al. 2024. Arthritis & rheumatology (Hoboken, N.J.). Volume 76(6); pages/article 973-983. DOI: 10.1002/art.42811.

Read more →
Source

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials

Published in Pittas AG et al (2023).

Publication details

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Pittas AG et al. 2023. Annals of internal medicine. Volume 176(3); pages/article 355-363. DOI: 10.7326/m22-3018.

Read more →
Source

Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial

Published in Joseph P et al (2023).

Publication details

Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial. Joseph P et al. 2023. Nutrition, metabolism, and cardiovascular diseases : NMCD. Volume 33(2); pages/article 434-440. DOI: 10.1016/j.numecd.2022.11.001. Abstract-level background only; the complete principal paper was unavailable for appraisal.

Read more →
Source

Vitamin D Supplementation and Muscle Power, Strength and Physical Performance in Older Adults: A Randomized Controlled Trial

Published in Houston DK et al (2023).

Publication details

Vitamin D Supplementation and Muscle Power, Strength and Physical Performance in Older Adults: A Randomized Controlled Trial. Houston DK et al. 2023. The American journal of clinical nutrition. Volume 117(6); pages/article 1086-1095. DOI: 10.1016/j.ajcnut.2023.04.021. Abstract-level background only; the complete principal paper was unavailable for appraisal.

Read more →